H.C. Wainwright updated the firm’s rating on Applied DNA Sciences from Buy to Under Review while removing its price target post the Q3 report. While the potential expansion of Linear Mpox assay could bring in additional sales, H.C. Wainwright is not confident that it could help the company’s revenue resume meaningful growth, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APDN: